{
  "abstract": "Introduction: Alpinia officinarum Hance and its diarylheptanoid metabolite, (R)-5-hydroxy-1,7-diphenyl-3-heptanone (DPHC), have hypoglycemic and hypolipidemic effects to ameliorate T2DM with insulin resistance (IR). However, the mechanisms by which DPHC ameliorates adipose IR associated with lipid metabolism disorders are not yet fully elucidated.\n\nMethods: DPHC was evaluated in dexamethasone-induced IR-3T3-L1 adipocytes and db/db mice. Exploratory network analysis was used to generate candidate mechanisms.\n\nResults: In IR-3T3-L1 adipocytes, DPHC increased glucose consumption and 2-NBDG uptake, reduced lipid accumulation and inflammatory-marker expression, and increased measured PPARγ and insulin-signaling-associated molecular markers. GW9662 attenuated several cellular effects of DPHC, supporting the involvement of a PPARγ-dependent component. In db/db mice, oral DPHC administration at 80 or 140 mg/kg/day reduced lipid accumulation and improved measured serum lipid-related endpoints. Pocket-directed docking to the DPHC-bound PPARγ ligand-binding domain, together with a single 100-ns molecular-dynamics trajectory, generated a structurally plausible binding pose.\n\nConclusion: The findings support a testable model in which DPHC may alleviate adipocyte insulin resistance partly through PPARγ-associated PI3K/AKT regulation.",
  "abstract_shown": true,
  "affiliations": [
    "Key Laboratory of Emergency and Trauma of Ministry of Education, Department of Hepatopancreatobiliary Aurgery, The First Affiliated Hospital, Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, School of Pharmaceutical Sciences, Hainan Medical University",
    "Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Hainan Academy of Medical Sciences, Hainan Medical University",
    "Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Qiongshen Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Yinghuan Wang"
    },
    {
      "affs": [
        1
      ],
      "name": "Jie Jiang"
    },
    {
      "affs": [
        0
      ],
      "name": "Peixia He"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhenrui Xie"
    },
    {
      "affs": [
        2
      ],
      "name": "Mingyan Zhou"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhuoxian Deng"
    },
    {
      "affs": [
        0
      ],
      "name": "Junqing Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Xuguang Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Qiushi Yin"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3z6qnptmw5fcb.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1934799",
  "fulltext_url": "https://europepmc.org/articles/PMC13713682",
  "id": "3z6qnptmw5fcb",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1934799/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "1312|Peroxisome Proliferator-Activated Receptors"
    ]
  ],
  "openalex": "W7221761439",
  "pdf_url": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1934799/pdf",
  "pmcid": "PMC13713682",
  "pmid": "42952998",
  "published": "2026-10-14",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/3z6qnptmw5fcb.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:06Z",
      "native_id": "10.3389/fphar.2026.1934799",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1934799/full"
    },
    {
      "first_seen": "2026-10-31T00:20:41Z",
      "native_id": "MED:42952998",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42952998"
    },
    {
      "first_seen": "2026-10-31T12:24:11Z",
      "native_id": "PMC13713682",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fphar.2026.1934799"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|Peroxisome Proliferator-Activated Receptors",
      "subfield": "molecular-biology"
    }
  ],
  "title": "A diarylheptanoid from Alpinia officinarum ameliorates insulin resistance in 3T3-L1 adipocytes and db/db mice through modulation of PPARγ/PI3K/AKT signaling pathway",
  "title_text": "A diarylheptanoid from Alpinia officinarum ameliorates insulin resistance in 3T3-L1 adipocytes and db/db mice through modulation of PPARγ/PI3K/AKT signaling pathway",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:21:18Z",
  "url": "https://research.draconitic.com/paper/3z6qnptmw5fcb",
  "venue": "Frontiers in Pharmacology",
  "versions": []
}